PMID- 15514588
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20141120
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 144
IP  - 4
DP  - 2004 Oct
TI  - Generation of a human leukocyte antigen-A24-restricted antitumor cell with the 
      use of SART-1 peptide and dendritic cells in patients with malignant brain 
      tumors.
PG  - 201-7
AB  - Dendritic cells (DCs) can be the principal initiators of antigen-specific immune 
      responses. In this study, we attempted to generate cytotoxic T-lymphocytes (CTLs) 
      using DCs pulsed with SART-1(254) peptide. Peripheral-blood mononuclear cells 
      (PBMCs) and tumor-infiltrating mononuclear cells (TIMCs) were obtained from 11 
      patients with brain tumors expressing human leukocyte antigen (HLA)-A24. After 
      stimulation with SART-1(254) peptide, CTLs showing over 15% were observed in one 
      of 4 patients with gliomas and in 4 of 7 patients with metastatic brain tumors. 
      Furthermore, exposure to DCs pulsed with SART-1(254) peptide increased the 
      killing activity of these CTLs by 28.7% and 37.5%, respectively. We conclude that 
      DCs pulsed with SART-1(254) peptide are effective in generating 
      HLA-A24-restricted antitumor cells.
FAU - Yoshida, Seiichi
AU  - Yoshida S
AD  - Department of Neurosurgery, Niigata Cancer Hospital, Kawagishi-chou, Japan. 
      brain@niigata-cc.niigata.jp
FAU - Tanaka, Ryuichi
AU  - Tanaka R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Ribonucleoproteins, Small Nuclear)
RN  - 0 (SART1 protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Antigens, Neoplasm/*administration & dosage
MH  - Brain Neoplasms/*immunology/secondary/*therapy
MH  - Cytotoxicity Tests, Immunologic
MH  - Dendritic Cells/drug effects/*immunology
MH  - Glioma/immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage
MH  - HLA-A Antigens/*metabolism
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunotherapy
MH  - In Vitro Techniques
MH  - Interleukin-4/administration & dosage
MH  - Lung Neoplasms
MH  - Lymphocyte Activation
MH  - Melanoma/immunology/secondary/therapy
MH  - Recombinant Proteins
MH  - Ribonucleoproteins, Small Nuclear/*administration & dosage
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tumor Necrosis Factor-alpha/administration & dosage
EDAT- 2004/10/30 09:00
MHDA- 2004/12/16 09:00
CRDT- 2004/10/30 09:00
PHST- 2004/10/30 09:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/10/30 09:00 [entrez]
AID - S0022214304001714 [pii]
AID - 10.1016/j.lab.2004.06.003 [doi]
PST - ppublish
SO  - J Lab Clin Med. 2004 Oct;144(4):201-7. doi: 10.1016/j.lab.2004.06.003.